BTK and autoimmune thrombocytopenic purpura: Several BTK inhibitors are in clinical development for ITP, including orelabrutinib, which has shown promising preliminary efficacy in Phase I/II trials [NCT05124028, NCT05020288, NCT05232149] and is currently being evaluated in a Phase III study [NCT06004856].